Zobrazeno 1 - 10
of 199
pro vyhledávání: '"Morey, Adrienne"'
Publikováno v:
In Pathology March 2024 56(2):147-157
Autor:
McKenzie, Catriona A., Gupta, Ruta, Jackett, Louise, Anderson, Lyndal, Chen, Vivien, Dahlstrom, Jane E., Dray, Michael, Farshid, Gelareh, Hemmings, Chris, Karim, Rooshdiya, Kench, James G., Klebe, Sonja, Kramer, Nicole, Kumarasinghe, Priyanthi, Maclean, Fiona, Morey, Adrienne, Nguyen, Minh Anh, O'Toole, Sandra, Rowbotham, Beverley, Salisbury, Elizabeth L.C., Scolyer, Richard A., Stewart, Katie, Waring, Lynette, Cooper, Caroline L., Cooper, Wendy A.
Publikováno v:
In Pathology October 2023 55(6):760-771
Autor:
Webb, Fiona, Morey, Adrienne, Mahler-Hinder, Collete, Georgousopoulou, Ekavi, Koo, RayMun, Pati, Nalini, Talaulikar, Dipti
Publikováno v:
In Cancer Genetics June 2023 274-275:75-83
Autor:
Ng, Jun Yen, Mokoonlall, Mridula, Kawatu, Hana, Ayyalil, Fathima, Perera, Chandima, Morey, Adrienne, Pati, Nalini K.
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports; 7/30/2024, p1-4, 4p
Autor:
Kumarasinghe, M. Priyanthi, Morey, Adrienne, Bilous, Michael, Farshid, Gelareh, Francis, Glenn, Lampe, Guy, McCue, Glenda, Von Neumann-Cosel, Vita, Fox, Stephen B.
Publikováno v:
In Pathology October 2017 49(6):575-581
Autor:
SAMA Investigators, Mallon, Patrick W. G., Unemori, Patrick, Sedwell, Rebecca, Morey, Adrienne, Rafferty, Martina, Williams, Kenneth, Chisholm, Donald, Samaras, Katherine, Emery, Sean, Kelleher, Anthony, Cooper, David A., Carr, Andrew
Publikováno v:
The Journal of Infectious Diseases, 2005 May . 191(10), 1686-1696.
Externí odkaz:
https://www.jstor.org/stable/30078095
Autor:
Kawatu, Hana A., Bareis, Kate, Brown, Michael, Cherian, Maya, Fadia, Mitali, Hallam, Lavinia, Jain, Sanjiv, Llewellyn, Huw, Loh, Daphne, Mittal, Namita, Morey, Adrienne, Pluschke, Anja, Srivastava, Divya, Dahlstrom, Jane E.
Publikováno v:
In Pathology March 2022 54 Supplement 1:S34-S34
Publikováno v:
BMJ Case Reports; Jul2021, Vol. 14 Issue 7, p1-6, 6p
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 555 (2012)
Abstract Background Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metasta
Externí odkaz:
https://doaj.org/article/b62e83969b7749f3922f7860c04e4c0b